December 01, 2016
Sandoz, Inc has announced a voluntary, firm-initiated recall of Ceftriaxone Injection, according to the latest Drug Enforcement Report (November 30, 2016) released by the US Food and Drug Administration.
Ceftriaxone is an injection delivered intravenously or intramuscularly to treat infections caused by bacteria from sexually transmitted diseases, pelvic inflammatory disease, meningitis, as well as infections of the lungs ears, skin, urinary tract, blood, bones, joints, and abdomen.
The recall was initiated on October 10, 2016 due to missing labeling errors. Specifically, it would appear the drug was shipped without any labeling information, which could confuse consumers and pose significant risks for patients due to a lack of adequate information.
The recall was categorized as class III, indicating that exposure to the Ceftriaxone Injection is unlikely to cause adverse health consequences.—Sean McGuire